Phreesia price target raised to $30 from $28 at JMP Securities

JMP Securities raised the firm’s price target on Phreesia to $30 from $28 and keeps an Outperform rating on the shares after hosting a series of investor meetings in San Francisco with CFO Balaji Gandhi. Gandhi says business is good and Phreesia continues to have good traction with the provider community, the analyst tells investors in a research note. The firm continues to like Phreesia, as it has a strong market position and is a leading brand as evidenced by the company facilitating more than 150M visits, or more than 10% of patient visits in the U.S. in FY24.